Keyword: Myovant Sciences
A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.
Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.
The drug comfortably beat placebo against a slew of efficacy endpoints and posted comparable safety and tolerability to the control.
Late-stage Japanese data has reinforced positive phase 2 results in the U.S. for Takeda and Myovant’s hormonal therapy in uterine fibroids.
Ex-Novo exec Høiland became Radius' CEO, ex-Sanofi Genzyme CEO Meeker joined Trevi as chairman, Myovant tapped four execs with Big Pharma experience.
Swiss biotech Myovant Sciences is celebrating after its lead hormonal therapy relugolix aced a mid-stage trial in uterine fibroids, adding to positive studies in prostate cancer.
The IPO raised the offer price and the number of shares sold with backing from new investors Pfizer and BB Biotech.